First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
1FDA regulatory milestones - 510(k) or PMA submission timing, clearance decisions, and any clinical hold or additional data requests
2Clinical trial data releases - procedural success rates, complication rates, conversion to open surgery rates, and comparative outcomes versus da Vinci system
3Cash runway updates and financing announcements - equity raises, debt facilities, or strategic partnerships that extend operational runway beyond current 12-18 month estimate
4Commercial partnership announcements - hospital system commitments, key opinion leader endorsements, or distribution agreements
5Competitive developments - Intuitive Surgical's single-port system (da Vinci SP) adoption rates and new entrants in miniaturized robotics space
6Capital equipment sales (robotic surgical systems) - not yet commercialized, estimated $1.0-1.5M per unit based on industry comparables
7Recurring instrument and accessory sales per procedure - estimated $1,500-2,500 per procedure based on surgical robotics industry standards
8Service contracts and maintenance agreements - typically 10-15% of capital equipment price annually
speculative growth - attracts venture-style investors willing to accept binary outcomes (FDA approval/commercial success vs.
High sensitivity through multiple channels: (1) Valuation compression - pre-revenue growth stocks trade on discounted future cash flows…
Watch on earnings: Monthly cash burn rate and total cash/equivalents balance - signals financing urgency, FDA submission date announcements and regulatory correspondence outcomes, Clinical trial procedural success rates and adverse event reporting.
One Sentence Summary:
Vicarious Surgical: the story is balanced — fda regulatory milestones - 510(k) or pma submission timing, clearance decisions, and any clinical hold or additional data requests.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.